Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
Status:
Completed
Trial end date:
2008-03-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and effectiveness of GI262570 compared to
placebo (a pill that looks exactly like GI262570 but contains no active medicine) in
improving specific tests that indicate the degree of liver fibrosis (scarring). Subjects who
are enrolled in the study must have had prior treatment with interferon (either pegylated or
standard interferon) plus ribavirin for at least 12 weeks to treat their hepatitis C, but
either failed to clear the virus or didn't tolerate the treatment.